Akebia Therapeutics, Inc. (AKBA) Aktienanalyse

Unternehmensübersicht

Akebia Therapeutics, Inc. operates as a biopharmaceutical enterprise dedicated to the development and commercialization of therapeutic solutions specifically designed for patients suffering from kidney diseases. Within the broader Healthcare sector, the company functions within the specialized industry of Drug Manufacturers - Specialty & Generic, positioning itself to address niche medical needs with proprietary oral medications. The company's operational scale is defined by a market capitalization of $358.96 million, an annual revenue of $236.20 million, and a workforce comprising 194 employees. These financial figures indicate that Akebia holds a mid-cap status within the pharmaceutical landscape, reflecting a substantial asset base that supports significant research and development activities while maintaining a relatively lean organizational structure compared to large-cap peers.

Finanzielle Gesundheit

The financial performance of the company over the trailing twelve months demonstrates a revenue stream of $236.20 million, which contrasts with a net income of -$5,345,000 and an EBITDA of $27.27 million. This significant divergence between positive revenue and negative net income reveals a cost structure where operating expenses and taxes likely exceed gross profits, resulting in a loss for the period despite strong top-line sales. Despite the net loss, the company generates a robust free cash flow of $68.61 million, which provides essential financial flexibility to fund ongoing clinical trials and commercialization efforts without immediate reliance on external equity financing. Profitability metrics highlight a gross margin of 82.9%, indicating highly efficient production and pricing of its drug portfolio, while an operating margin of -10.5% and a profit margin of -2.3% reflect the heavy investment in research and development typical of the biotechnology sector. The balance sheet shows a cash position of $184.84 million against total debt of $198.78 million, resulting in a debt-to-equity ratio of 609.57, which characterizes a leveraged capital structure rather than a conservative one. Liquidity analysis reveals a current ratio of 1.55, suggesting the company possesses sufficient current assets to cover its short-term liabilities with a moderate safety margin. Return on equity is listed as N/A due to the net loss position, whereas return on assets stands at 5.4%, indicating that the company is generating a positive return on its total asset base despite the reported net income deficit.

Bewertungsanalyse

Valuation multiples for Akebia Therapeutics, Inc. show a trailing twelve-month P/E ratio of N/A and a forward P/E of -14.11, a disparity that implies the market is pricing in future earnings recovery or continued losses in the immediate forward period. The price-to-book ratio is calculated at 10.89, suggesting that the stock trades at a significant premium relative to its tangible book value, a common characteristic for biopharmaceutical firms with valuable intellectual property portfolios. Alternative valuation metrics such as a price-to-sales ratio of 1.52 and an EV/EBITDA of 13.67 offer additional context, indicating that investors are willing to pay a multiple of current sales and earnings before interest, taxes, depreciation, and amortization to acquire the company. Price metrics define a trading range between a 52-week high of $4.08 and a 52-week low of $1.14, though the specific current price level relative to this range is not provided in the available data points. The beta value is recorded at 0.40, which signifies that the stock exhibits substantially lower price volatility relative to the broader market, moving with less intensity than the overall index.

Growth & Income

Growth metrics indicate a revenue growth year-over-year of 23.9%, while earnings growth is listed as N/A, implying that top-line expansion is currently outpacing the stabilization of profitability or that earnings metrics are not yet positive enough to calculate a standard growth rate. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all earnings to reinvest into growth initiatives such as drug development and commercial expansion rather than distributing income to shareholders. This reinvestment strategy is typical for biopharmaceutical companies in the growth phase, prioritizing long-term pipeline development over immediate income generation for investors. The overall growth and income profile is characterized by strong sales expansion supported by a non-dividend policy, aligning the company's trajectory with capital appreciation rather than current yield.